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See Article, pages 1073–1079Single nucleotide polymorphisms (SNPs) are nucleotide varia-
tions occurring at the DNA level in each cell of a human being.
In association with environmental factors, SNPs model the phe-
notypic diversity in humans but are also involved in susceptibil-
ity to several illnesses including cancer [1]. The association
between SNPs and hepatocellular carcinoma (HCC) has been
tested in case-control and prospective cohorts on a hypothesis-
driven basis in candidate gene studies. In this setting, numerous
variants affecting inﬂammatory pathways, oxidative stress, iron
metabolism or DNA repair mechanisms have been linked with
HCC development in cirrhotic patients [2]. In addition, genome-
wide association studies (GWAS) used to blindly test the associ-
ation between thousands of SNPs and HCC have identiﬁed several
new variants in genes such as MICA, STAT4, HLADQ, and DEPDC5
thought to modulate HCC predisposition [2]. However, these
unsupervised GWAS approaches have only been conducted in
Asian populations, with liver cancer related to hepatitis B or C
virus (HBV or HCV) infection by far the most common clinical set-
ting. In contrast, despite the high incidence of HCC in alcoholic
cirrhosis in Europe and its continuing increase in developing
countries [4], the genetic determinants of alcoholic carcinogene-
sis have been poorly investigated and only with candidate gene
approaches [3].
Components of the metabolic syndrome such as obesity or
diabetes mellitus and their hepatic consequences, particularly
steatosis, are associated with an increased risk of HCC occurrence
in patients with cirrhosis [5]. These features might be only cofac-
tors in viral carcinogenesis, during which the direct oncogenic
effects of HBV or HCV are well demonstrated [6], but their impli-
cation in liver cancer development in patients with nonalcoholic
steatohepatitis (NASH) or alcoholic liver disease (ALD) is pivotal
[7,8]. However, a direct link between the amount of lipid accu-
mulation in the liver and development of HCC has never been
clearly demonstrated, which suggests a more subtle than
direct effect of hepatic triglyceride overload on carcinogenicJournal of Hepatology 20
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Open access under CC BY-NC-ND license.mechanisms. Indeed, increased fatty acid synthesis and accumu-
lation of lipid droplets are frequent in transformed hepatocytes
[9] and likely interfere with cellular signalling pathways by alter-
ing regulation of gene transcription implicated in the oncogenic
process [10].
The identiﬁcation of the SNP rs738409 in the adiponutrin/
patatin-like phospholipase 3 (PNPLA3) gene by GWAS of patients
with NASH and ALD provided a robust link between this variant
associated with intracellular triglyceride accumulation and alco-
hol-induced liver cancer in European populations [11]. In parallel,
recent GWAS identiﬁed other loci, including neurocan (NCAN),
associated with liver fat content [12] and progression of nonalco-
holic fatty liver disease (NAFLD) [13]. Some of the variants were
associated with distinct changes in serum lipid levels, which sug-
gest different and speciﬁc impacts on lipid metabolism and
NAFLD progression. In particular, the T allele of NCAN
rs2228603 was reported to promote hepatic triglyceride accumu-
lation as well as reduced serum triglyceride and low-density lipo-
protein cholesterol levels, which may seem counterintuitive at
ﬁrst sight [12].
In this issue of the Journal of Hepatology, Nischalke et al. [14]
report on their well-designed case-control study testing the
association of NCAN polymorphism and susceptibility to HCC in
German patients with alcoholic cirrhosis. The authors describe
a signiﬁcant association between the T allele of NCAN rs2228603
polymorphism and HCC in these patients (odds ratio [OR] 2.29).
This study presents the advantage of meeting several methodo-
logical quality criteria. In particular, the association seemed to
be restricted to alcoholic carcinogenesis because HCV-infected
patients harbouring the T allele did not show increased preva-
lence of liver cancer. Moreover, a validation set of ALD patients
conﬁrmed the association between NCAN rs2228603 and HCC.
The authors also took into account variations in PNPLA3, and were
thus able to observe higher rates of HCC among carriers of both
the NCAN-T and PNPLA3-G risk variants as compared with car-
riage of only one or none of these genetic traits (OR 1.891 and
4.575, respectively). Finally genotype–phenotype correlations in
liver samples highlighted a possible involvement of the extra-
cellular matrix NCAN in ALD progression, although the
mechanisms of carcinogenesis remain to be clariﬁed.14 vol. 61 j 971–972
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NCAN encodes for a chondroitin sulphate proteoglycan that
accumulates in the extracellular matrix [13]. However, the mech-
anism that links NCAN and lipid homeostasis remains elusive.
The NCAN locus contains at least 20 genes in a 500-kb region on
chromosome 19p13 [15]. A ﬁner mapping of this region with gen-
ome-wide exome chip genotyping recently revealed TM6SF2
rs58542926 as a distinct locus in strong linkage disequilibrium
withNCAN that is also implicated in hepatic triglyceride accumula-
tion and NAFLD progression [16]. Indeed, the p.Glu167Lys TM6SF2
polymorphism seems to compete with the NCAN polymorphism
in this region as a culprit for NAFLD susceptibility. Subsequent
validation in patients with NASH conﬁrmed its effect on ﬁbrosis
progression and suggested a possible impact onHCC development,
although issues of lowpowerwith insufﬁcient sample sizemust be
acknowledged [17]. The extent to which NCAN and/or TM6SF2
variants act as direct modiﬁers of liver fat content and possibly
carcinogenesis warrants further explorations.
Interestingly, in the Nischalke et al. study, the NCAN
rs2228603 polymorphism and PNPLA3 I148M variant were inde-
pendently associated with increased prevalence of HCC among
two genotyped cohorts and had additive value in stratifying
patients by presence of liver cancer. This approach highlights
the current challenge of deciphering how the combination of
inherited factors might collectively deﬁne an individual genomic
risk prediction of liver cancer in cirrhotic patients. Taken
together, these data also underline the potential impact of lipid
metabolism and steatosis in liver carcinogenesis. Clearly, the
knowledge of a genetic predisposition to HCC in alcoholic cirrho-
sis and especially the NCAN polymorphism adds a new level to
our understanding of the mechanisms of liver carcinogenesis
related to excessive alcohol intake. Dissecting the complex
genetic regulations of lipid metabolism and its possible inﬂuence
on hepatocarcinogenesis might reveal speciﬁc targets for future
therapies based on host susceptibility. However, whether
PNPLA3, NCAN or TM6SF2 variants promote HCC emergence by
creating a favourable pro-carcinogenic environment or by specif-
ically triggering the oncogenic process is still enigmatic. Mecha-
nistic studies should unravel speciﬁc impaired biological
pathways that might account for the repeated reports describing
the speciﬁc associations between these host factors and the
emergence of liver cancer in ALD patients.
In addition, the evaluation of the clinical impact of this genetic
heterogeneity on patient care requires validation in prospective
cohorts of cirrhotic patients regularly screened for HCC. Such
studies would bypass the usual biases of case–control studies
and take into account all confounding factors affecting the course
of cirrhosis. The identiﬁcation of SNPs could allow for better pre-
dicting HCC occurrence in these patients, help stratify popula-
tions in various HCC risk classes and identify subgroups that
might beneﬁt from chemopreventive procedures or speciﬁc
screening strategies based on inter-individual susceptibility.
Moreover, downstream of SNPs and constitutional variants,
somatic genetic alterations draw the mutational landscape of
hepatocellular carcinoma [18]. Future studies will link genetic
variations at the constitutional level with somatic genetic altera-
tions or molecular subclasses observed in one cancer type, as
described with the different molecular subtypes of breast cancer
[19,20]. Associated with somatic genetic alterations of HCC, con-
stitutional SNPs will be important determinants used to predict
tumour recurrence after curative procedures, response to tar-
geted therapies and drug toxicity in the future.972 Journal of Hepatology 201Conﬂict of interest
The authors who have taken part in this study declared that they
do not have anything to disclose regarding funding or conﬂict of
interest with respect to this manuscript.References
[1] Dong LM, Potter JD, White E, Ulrich CM, Cardon LR, Peters U. Genetic
susceptibility to cancer: the role of polymorphisms in candidate genes. JAMA
2008;299:2423–2436.
[2] Nahon P, Zucman-Rossi J. Single nucleotide polymorphisms and risk of
hepatocellular carcinoma in cirrhosis. J Hepatol 2012;57:663–674.
[3] Nahon P, Sutton A, Rufat P, Ziol M, Akouche H, Laguillier C, et al.
Myeloperoxidase and superoxide dismutase 2 polymorphisms comodulate
the risk of hepatocellular carcinoma and death in alcoholic cirrhosis.
Hepatology 2009;50:1484–1493.
[4] Lim SS, Vos T, Flaxman AD, Danaei G, Shibuya K, Adair-Rohani H, et al. A
comparative risk assessment of burden of disease and injury attributable to
67 risk factors and risk factor clusters in 21 regions, 1990–2010: a
systematic analysis for the Global Burden of Disease Study 2010. Lancet
2012;380:2224–2260.
[5] Pekow JR, Bhan AK, Zheng H, Chung RT. Hepatic steatosis is associated with
increased frequency of hepatocellular carcinoma in patients with hepatitis
C-related cirrhosis. Cancer 2007;109:2490–2496.
[6] McGivern DR, Lemon SM. Virus-speciﬁc mechanisms of carcinogenesis in
hepatitis C virus associated liver cancer. Oncogene 2011;30:1969–1983.
[7] Baffy G, Brunt EM, Caldwell SH. Hepatocellular carcinoma in non-alcoholic
fatty liver disease: an emerging menace. J Hepatol 2012;56:1384–1391.
[8] Morgan TR, Mandayam S, Jamal MM. Alcohol and hepatocellular carcinoma.
Gastroenterology 2004;127:S87–S96.
[9] Menendez JA, Lupu R. Fatty acid synthase and the lipogenic phenotype in
cancer pathogenesis. Nat Rev Cancer 2007;7:763–777.
[10] Vinciguerra M, Carrozzino F, Peyrou M, Carlone S, Montesano R, Benelli R,
et al. Unsaturated fatty acids promote hepatoma proliferation and progres-
sion through downregulation of the tumor suppressor PTEN. J Hepatol
2009;50:1132–1141.
[11] Trepo E, Nahon P, Bontempi G, Valenti L, Falleti E, Nischalke HD, et al.
Association between the PNPLA3 (rs738409 C>G) variant and hepatocellular
carcinoma: Evidence from a meta-analysis of individual participant data.
Hepatology 2014;59:2170–2177.
[12] Speliotes EK, Yerges-Armstrong LM, Wu J, Hernaez R, Kim LJ, Palmer CD,
et al. Genome-wide association analysis identiﬁes variants associated with
nonalcoholic fatty liver disease that have distinct effects on metabolic traits.
PLoS Genet 2011;7:e1001324.
[13] Gorden A, Yang R, Yerges-Armstrong LM, Ryan KA, Speliotes E, Borecki IB, et al.
Genetic variation at NCAN locus is associatedwith inﬂammation and ﬁbrosis in
non-alcoholic fatty liver disease inmorbid obesity. HumHered 2013;75:34–43.
[14] Nischalke HD, Lutz P, Kramer B, Sohne J, Muller T, Rosendahl J, et al. A
common polymorphism in the NCAN gene is associated with hepatocellular
carcinoma in alcoholic liver disease. J Hepatol 2014;61:1073–1079.
[15] Kathiresan S, Melander O, Guiducci C, Surti A, Burtt NP, Rieder MJ, et al. Six
new loci associated with blood low-density lipoprotein cholesterol, high-
density lipoprotein cholesterol or triglycerides in humans. Nat Genet
2008;40:189–197.
[16] Kozlitina J, Smagris E, Stender S, Nordestgaard BG, Zhou HH, Tybjaerg-
Hansen A, et al. Exome-wide association study identiﬁes a TM6SF2 variant
that confers susceptibility to nonalcoholic fatty liver disease. Nat Genet
2014;46:352–356.
[17] Liu YL, Reeves HL, Burt AD, Tiniakos D, McPherson S, Leathart JB, et al.
TM6SF2 rs58542926 inﬂuences hepatic ﬁbrosis progression in patients with
non-alcoholic fatty liver disease. Nat Commun 2014;5:4309.
[18] Guichard C, Amaddeo G, Imbeaud S, Ladeiro Y, Pelletier L, Maad IB, et al.
Integrated analysis of somatic mutations and focal copy-number changes
identiﬁes key genes and pathways in hepatocellular carcinoma. Nat Genet
2012;44:694–698.
[19] Haiman CA, Chen GK, Vachon CM, Canzian F, Dunning A, Millikan RC, et al. A
common variant at the TERT-CLPTM1L locus is associated with estrogen
receptor-negative breast cancer. Nat Genet 2011;43:1210–1214.
[20] Reeves GK, Travis RC, Green J, Bull D, Tipper S, Baker K, et al. Incidence of
breast cancer and its subtypes in relation to individual and multiple low-
penetrance genetic susceptibility loci. JAMA 2010;304:426–434.4 vol. 61 j 971–972
